Robert F. Kennedy Jr. aims to shift U.S. health policy towards psychedelics and cannabis access

Robert F. Kennedy Jr. has been nominated by Donald Trump to lead the Department of Health and Human Services. Kennedy has expressed skepticism about pharmaceuticals and criticized the FDA for limiting access to psychedelics. He aims to shift focus from traditional medications to alternative treatments. Kennedy's views have raised concerns among public health experts. They worry he may restrict access to established medications like Adderall and SSRIs, which many rely on. His plans include legalizing cannabis and promoting wellness farms for addiction recovery. Kennedy's approach to healthcare could challenge recent FDA decisions, particularly regarding psychedelic treatments. Experts caution that rushing approvals for these therapies could lead to safety issues, emphasizing the need for thorough research before widespread implementation.